南方财经2月2日电，利扬芯片(688135.SH)1月31日披露2026年度向特定对象发行A股股票预案，计划向 不超过35名特定投资者发行股票，募集资金总额不超过97,000万元，用于扩展集成电路测试产能及先进 工艺研发。募集资金在扣除发行费用后拟投入四个项目：其中70,000万元用于东城利扬芯片集成电路测 试项目，旨在扩大芯片测试服务能力；8,000万元用于晶圆激光隐切项目（一期），拓展晶圆切割业 务；10,000万元用于异质叠层先进封装工艺研发项目，联合叠铖光电开发高端图像传感芯片技术；9,000 万元用于补充流动资金及偿还银行贷款，以优化财务结构。财务数据显示，利扬芯片2024年度归属于母 公司股东的净利润为-6,161.87万元，但2025年经营状况改善，1-9月实现归属于母公司股东的净利润 75.47万元，扣除非经常性损益后为-191.44万元，公司称已在2025年第三季度末实现连续两季度盈利。 公司首次公开发行股票募集资金净额47,094.26万元已于2025年9月30日使用完毕，主要用于芯片测试产 能建设、研发中心及补充流动资金，其中芯片测试产能建设项目累计实现收益33,279.12万元，但未达 ...

（记者 王晓波） 每经头条（nbdtoutiao）——中国无人驾驶"军团"，"武装"阿布扎比 每经AI快讯，利扬芯片1月30日晚间发布公告称，本次向特定对象发行股票方案已经公司第四届董事会 第十七次会议审议通过，本次向特定对象发行的发行对象为不超过35名（含35名）符合法律法规、中国 证监会、上海证券交易所规定条件的特定对象，其中，本次向特定对象发行股票的数量按照募集资金总 额除以发行价格确定，且不超过本次发行前公司总股本的20%，即不超过约4069万股（含本数）。本次 向特定对象发行股票的发行价格为不低于定价基准日前二十个交易日公司股票交易均价的80%。本次发 行拟募集不超过9.7亿元，募集资金用于以下用途：东城利扬芯片集成电路测试项目，总投资约13.15亿 元，拟投入募集资金7亿元；异质叠层先进封装工艺研发项目，总投资1亿元，拟投入募集资金1亿元； 晶圆激光隐切项目（一期）项目，总投资1亿元，拟投入募集资金8000万元；补充流动资金及偿还银行 贷款项目，总投资9000万元，拟投入募集资金9000万元。 ...

Core Viewpoint - Dagang Co., Ltd. announced on November 6 that its wholly-owned subsidiary, Shanghai Minai, has increased its investment to gain control of Aike Integrated, which will enhance synergies in customer resources, technology accumulation, and capacity layout in the integrated circuit testing field [2] Group 1 - The investment will primarily be used to purchase high-end testing equipment, which is expected to expand the company's market scale and competitiveness in the testing market [2] - This strategic move is considered significant for the long-term development of the company [2]

Core Viewpoint - The company aims to enhance its competitiveness in the integrated circuit testing sector by increasing its investment in Jiangsu Aike Integrated Circuit Co., Ltd. through its wholly-owned subsidiary, Shanghai Minai Semiconductor Co., Ltd. [1] Group 1: Investment Details - The company plans to invest 90 million yuan (approximately 13.5 million USD) to increase the registered capital of Jiangsu Aike by 37.1526 million yuan (approximately 5.6 million USD) [1] - After the capital increase, Jiangsu Aike's registered capital will rise from 10 million yuan to 47.1526 million yuan [1] - Shanghai Minai will hold 78.79% of Jiangsu Aike's shares, making it a subsidiary included in the company's consolidated financial statements [1] Group 2: Purpose of Investment - The funds from this capital increase will primarily be used for purchasing high-performance and high-reliability chip testing equipment [1] - The investment is aimed at expanding production capacity to support business growth [1]

Group 1 - Multiple listed companies in the Shanghai market have recently announced positive performance forecasts for the first three quarters of 2025, alongside significant R&D achievements, indicating a buildup of new growth momentum [1] - The semiconductor industry chain is experiencing a "full-chain resonance" effect, with various sectors showing growth vitality [1] - Anhui Xindong Link Micro System Co., Ltd. expects a net profit attributable to shareholders of 216 million to 264 million yuan for the first three quarters, representing a year-on-year increase of approximately 56.43% to 91.19% [1] - TaiLing Microelectronics (Shanghai) Co., Ltd. anticipates a revenue of about 766 million yuan for the first three quarters, a year-on-year increase of around 30%, with a net profit of approximately 140 million yuan, reflecting a growth rate of about 118% [1] - Shanghai Weicai Semiconductor Technology Co., Ltd. expects a consolidated revenue of 448 million yuan for July to September, a 44.4% increase year-on-year, and a total revenue of 1.083 billion yuan from January to September, up 46.22% year-on-year, indicating a positive trend in industry prosperity [1] Group 2 - R&D innovation is crucial for the development of companies on the Sci-Tech Innovation Board, with several firms recently announcing significant R&D results [2] - Sichuan Baili Tianheng Pharmaceutical Co., Ltd.'s subsidiary SystImmune has entered a global strategic cooperation agreement with Bristol-Myers Squibb for the iza-bren project, triggering an initial payment condition of 250 million USD [2] - SystImmune has also completed the first patient enrollment in a Phase III clinical trial for its innovative biological drug T-Bren (HER2ADC) targeting HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma [2] - Chengdu Huayi Electronics Technology Co., Ltd. has successfully launched a new RF transceiver chip, expanding its high-speed signal chain product line and market space [2]

Core Viewpoint - The report outlines the ongoing supervisory work conducted by Guangfa Securities for Guangdong Liyang Chip Testing Co., Ltd., emphasizing the company's compliance with regulations and the absence of any violations during the supervisory period [1][2][6]. Group 1: Supervisory Work - Guangfa Securities has established and effectively implemented a continuous supervision work system and plan for Liyang Chip [2]. - A continuous supervision agreement has been signed between the sponsor and Liyang Chip, clarifying the rights and obligations of both parties during the supervision period [2]. - The supervisory work includes daily communication, regular visits, on-site inspections, and due diligence [2][3]. Group 2: Compliance and Governance - Liyang Chip has adhered to legal and regulatory requirements, with no reported violations or breaches of commitments during the supervisory period [2][6]. - The company has established effective corporate governance and internal control systems, including financial management and auditing procedures [2][3]. Group 3: Financial Performance - For the first half of 2025, Liyang Chip reported operating revenue of 284.04 million yuan, a 23.09% increase compared to 2024 [15]. - The total profit for the same period was -8.95 million yuan, showing an improvement from -16.37 million yuan in the previous year [15]. - The net profit attributable to shareholders was -7.06 million yuan, compared to -8.44 million yuan in the same period last year [15]. Group 4: Risks and Challenges - The company faces core competitiveness risks due to rapid technological advancements in the integrated circuit industry, necessitating continuous talent development [6][7]. - Operational risks are present as the industry is capital-intensive, requiring significant investment in testing equipment to meet market demands [7][8]. - The company is also exposed to financial risks, including fluctuations in gross profit margins due to changes in product structure and cost structures [11][12]. Group 5: Research and Development - Liyang Chip has invested 37.31 million yuan in R&D in the first half of 2025, a decrease of 4.27% from the previous year [25]. - The R&D expenditure accounted for 13.13% of operating revenue, reflecting a decrease of 3.76 percentage points [25]. - The company has made significant progress in patent applications and software copyrights, enhancing its innovation capabilities [25][26]. Group 6: Market Position and Competitive Advantage - Liyang Chip has established a strong market position in the integrated circuit testing industry, benefiting from its diverse testing platforms and proximity to local chip design companies [17][20]. - The company emphasizes customer loyalty and interaction, which contributes to its competitive edge in the market [18][20]. - The strategic focus on emerging applications such as automotive electronics and high-performance computing positions the company for future growth [21][22].

Core Insights - Liyang Chip (SH.688135) reported a positive performance in its 2025 semi-annual report, showcasing revenue growth, reduced losses, and a significant quarterly breakthrough in the integrated circuit testing sector [1][2] Financial Performance - In the first half of 2025, the company achieved operating revenue of 284.04 million yuan, a substantial increase of 23.09% compared to the same period last year, indicating enhanced market competitiveness in the integrated circuit testing field [1] - The net profit attributable to shareholders was -7.06 million yuan, but the loss narrowed significantly compared to the previous year, reflecting a clear trend of improving profitability [1] - The net profit after deducting non-recurring gains and losses was -6.76 million yuan, indicating that the core business's profitability is gradually improving with minimal interference from non-recurring factors [1] Business Segmentation and Quarterly Analysis - The integrated circuit testing business generated operating revenue of 277.29 million yuan in the first half of 2025, a year-on-year growth of 21.85%, demonstrating the core competitiveness and sustainability of the company's main business [2] - In Q2 2025, the company achieved a record high quarterly revenue of 150.26 million yuan, reflecting increased market orders and significant progress in capacity release and customer expansion [2] - The net profit attributable to shareholders in Q2 2025 was 523,400 yuan, marking the first quarterly profit and indicating a turning point in the company's operations, transitioning from loss reduction to quarterly profitability [2] Future Outlook - Overall, Liyang Chip's performance in the first half of 2025 is commendable, with steady revenue growth, continuous loss reduction, and improved quarterly profitability, confirming the gradual release of development potential in the integrated circuit testing sector [2] - With the recovery of the integrated circuit industry's prosperity and the company's ongoing efforts in its core business, there is potential for further market share expansion and sustained improvement in profitability, ultimately creating more value for shareholders [2]

Core Viewpoint - The report highlights the financial performance and operational developments of Guangdong Leadyo IC Testing Co., Ltd. for the first half of 2025, emphasizing growth in revenue and the strategic importance of independent third-party integrated circuit testing in the semiconductor industry. Financial Performance - The company reported a revenue of approximately 284 million RMB for the first half of 2025, representing a 23.09% increase compared to the same period last year [4][5]. - The total profit for the period was approximately -8.95 million RMB, an improvement from -16.37 million RMB in the previous year [4][5]. - The net profit attributable to shareholders was approximately -7.06 million RMB, also showing improvement from -8.44 million RMB year-on-year [4][5]. - The company’s net assets increased by 1.82% to approximately 1.13 billion RMB compared to the end of the previous year [4][5]. Industry Overview - The company operates in the integrated circuit testing sector, which is classified under the "C3973 Integrated Circuit Manufacturing" category of the national economic industry classification [6][7]. - The integrated circuit testing industry is characterized by high capital intensity and requires significant investment in testing platforms and technology upgrades to meet the increasing complexity of chips [6][7]. - The demand for independent third-party testing services is growing due to the rising complexity of chips and the need for personalized testing solutions [6][7]. Technological Advancements - The company has developed 44 categories of chip testing solutions and completed mass testing for thousands of chip models, leveraging a vast database of testing data [8][9]. - The company focuses on high-performance chips, including CPU, GPU, and AI applications, and has established a competitive edge in various emerging product applications such as 5G communications and automotive electronics [8][9]. - Continuous investment in research and development is crucial for maintaining technological leadership and adapting to market demands [10][11]. Strategic Positioning - The company aims to enhance its market position by expanding its capabilities in automotive electronics, industrial control, and high-performance computing sectors [9][10]. - The establishment of long-term partnerships with chip design companies is essential for developing tailored testing solutions that meet specific product requirements [7][9]. - The company’s ability to quickly develop testing solutions in response to market needs is a significant competitive advantage [9][10].

Core Insights - Liyang Chip (688135) reported a revenue of 284 million yuan for the first half of 2025, representing a year-on-year growth of 23.09%, while the net profit attributable to shareholders was a loss of 7.06 million yuan, indicating a narrowing of losses compared to the previous year [1] - The company specializes in integrated circuit testing services, having developed 44 categories of testing solutions and completed mass production testing for thousands of chip models, with applications across various sectors including communications, computing, consumer electronics, automotive electronics, and industrial control [1] Business Performance - The revenue from integrated circuit testing services reached 277 million yuan in the first half of 2025, a year-on-year increase of 21.85%, with the second quarter achieving a record high of 150 million yuan in revenue [2] - The significant growth in testing revenue was driven by sustained demand from existing clients and the introduction of new products from newly acquired clients [2] - Revenue from wafer thinning services surged to 6.75 million yuan, marking a year-on-year increase of 111.61%, attributed to the company's strategic focus on wafer thinning and related technologies [2] - The company achieved a net profit of 523,400 yuan in the second quarter of 2025, reflecting improved profitability alongside rising revenues [2] Research and Development - Liyang Chip invested 37.31 million yuan in R&D during the reporting period, accounting for 13.13% of its revenue, emphasizing the importance of R&D in its growth strategy [3] - The company aims to address the imbalance in the integrated circuit testing sector, where there is a lack of full-process professional testing service providers to meet the high demand from design companies [3] - Future investments will focus on high-reliability testing capacities for GPUs, CPUs, AI, FPGAs, and automotive chips, enhancing the company's ability to provide efficient testing solutions and fostering a collaborative ecosystem within the industry [3]

Core Viewpoint - The company reported a net profit attributable to shareholders of 427 million yuan for the first half of 2025, representing a year-on-year increase of 98.73%, indicating strong growth driven by the expansion of mid-to-high-end products [1] Investment Highlights - The company maintains an "Overweight" rating with a target price of 56.75 yuan per share, supported by the expected ramp-up of CIS testing machines and storage testing machines in 2025-2026, leading to upward adjustments in EPS forecasts for 2025-2027, with EPS projected at 1.62, 2.08, and 2.64 yuan respectively, reflecting growth rates of 122.98%, 28.32%, and 26.82% [2] - The company focuses on integrated circuit testing equipment, expanding its product line to include digital testing equipment and various high-end applications, resulting in a revenue of 2.167 billion yuan for the first half of 2025, a year-on-year increase of 41.80% [2][3] - The company’s R&D investment for the first half of 2025 reached 577 million yuan, accounting for 26.65% of revenue, with a year-on-year increase of 35.38%, indicating a strong commitment to innovation [3] Product Performance - In the first half of 2025, the testing machine segment generated revenue of 1.250 billion yuan, a year-on-year increase of 34.30%, while the sorting machine segment achieved revenue of 709 million yuan, up 50.36% [3] - The company has developed new products in the AOI measurement system field, including the NanoX-6000 and NanoX-8000 series, which cater to critical measurement needs in the semiconductor and PCB sectors, respectively [3]